Use of DHEA and DHEA-sulfate for the treatment of chronic obstructive pulmonary disease
AssigneeEpigenesis Pharmaceuticals, Inc.
InventorJonathan W. Nyce
Life of this patent
Estimating the term…
Abstract
A method for treating or preventing chronic obstructive pulmonary disease (COPD) by using as active agent a non-glucorticoid steroid, analogue thereof, such as dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S), or their salts, in an amount effective for preventing or treating COPD.
Claims38
A method for treating or preventing chronic obstructive pulmonary disease comprising administering to a subject need of such treatment or prophylaxis a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of an active agent selected from a non-glucocorticoid steroid having the chemical formula
- 14
- wherein the broken line represents a single or a double bond;
- R is hydrogen or a halogen;
- the H at position 5 is present in the alpha or beta configuration or the compound of chemical formula I comprises a racemic mixture of both configurations;
- and R1 is hydrogen or SO2OM, wherein M is selected from the group consisting of H, Na, sulfatide
- 15
- wherein R2 and R3, which may be the same or different, are straight or branched (C1-C14) alkyl or glucuronide
- 16
- or a non-glucocorticoid steroid of the chemical formula
- 17
- wherein R1, R2, R3, R4, R5, R7, R8, R9, R10, R12, R13, R14 and R19 are independently H, OR, halogen, (C1-C10) alkyl or (C1-C10) alkoxy, R5 and R11 are independently OH, SH, H, halogen, pharmaceutically acceptable ester, pharmaceutically acceptable thioester, pharmaceutically acceptable ether, pharmaceutically acceptable thioether, pharmaceutically acceptable inorganic esters, pharmaceutically acceptable monosaccharide, disaccharide or oligosaccharide, spirooxirane, spirothirane, —OSO2R20, —OPOR20R21 or (C1-C10) alky, R5 and R6 taken together are ═O, R10 and R11 taken together are ═O;
- R15 is (1) H, halogen, (C1-C10) alkyl, or (C1-C10) alkoxy when R16 is —C(O)OR22, (2) H, halogen, OH or (C1-C10) alkyl when R16 is halogen, OH or (C1-C10) alkyl, (3) H, halogen, (C1-C10) alkyl, (C1-C10) alkenyl, (C1-C10) alkynyl, formyl, (C1-C10) alkanoyl or epoxy when R16 is OH, (4) OR, SH, H, halogen, pharmaceutically acceptable ester, pharmaceutically acceptable thioester, pharmaceutically acceptable ether, pharmaceutically acceptable thioether, pharmaceutically acceptable inorganic esters, pharmaceutically acceptable monosaccharide, disaccharide or oligosaccharide, spirooxirane, spirothirane, —OSO2R20 or —OPOR20R21 when R16 is H, or R15 and R16 taken together are =0;
- R17 and R18 are independently (1) H, —OH, halogen, (C1-C10) alkyl or —(C1-C10) alkoxy when R6 is H OR, halogen, (C1-C10) alkyl or —C(O)OR22, (2) H, (C1-C10alkyl)amino, ((C1-C10) alkyl)n amino-(C1-C10) alkyl, (C1-C10) alkoxy, hydroxy-(C1-C10) alkyl, (C1-C10) alkoxy-(C1-C10) alkyl, (halogen)m (C1-C10) alkyl, (C1-C10) alkanoyl, formyl, (C1-C10) carbalkoxy or (C1-C10) alkanoyloxy when R15 and R16 taken together are =0, (3) R17 and R18 taken together are =0;
- (4) R17 or R18 taken together with the carbon to which they are attached form a 3-6 member ring containing 0 or 1 oxygen atom;
- or (5) R15 and R17 taken together with the carbons to which they are attached form an epoxide ring;
- R20 and R21 are independently OH, pharmaceutically acceptable ester or pharmaceutically acceptable ether;
- R22 is H, (halogen)m (C1-C10) alkyl or (C1-C10) alkyl;
- n is 0, 1 or 2;
- and m is 1, 2 or 3;
- or pharmaceutically or veterinarily acceptable salts thereof.
Dependencies are inferred from the claim text.